medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2021-9-8-16medsovet-6243Research ArticleИММУНОТЕРАПИЯ ОПУХОЛЕЙIMMUNOTHERAPY IN ONCOLOGYИнгибитор PD-1 пролголимаб в лечении метастатической меланомы кожи: новые данные и опыт применения PD-1inhibitor prolgolimab in metastatic skin melanoma: recent data and experience of useРедакционнаяСтатьяEditorialArticle20210608202109816Copyright © Редакционная С., 20212021Редакционная С.Editorial A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/6243

Ежегодно в мире и в России растет заболеваемость меланомой кожи, в т. ч. доля метастатической меланомы. До недавнего времени для ее лечения использовались режимы химиотерапии. Появление в клинической практике иммунологических препаратов – анти-PD-1 и анти-CTLA-4 стало прорывом, поскольку они увеличили и время до прогрессирования, и общую выживаемость пациентов с метастатической меланомой. 11 ноября 2020 г. на XXIV Российском онкологическом конгрессе ведущие специалисты по меланоме собрались на сателлитном симпозиуме компании BIOCAD «Российская действительность. Как и чем лечить метастатическую меланому в реальной клинической практике?». Эксперты обсудили клинические рекомендации, выбор терапии у пациентов с наличием BRAF-мутаций, представили данные клинического исследования MIRACULUM моноклонального антитела пролголимаб и анонсировали наблюдательную программу FORA по оценке безопасности данного препарата.

.

ReferencesLarkin J.M.G., Chiarion-Sileni V., Gonzalez R., Grob J.J., Rutkowski P., Laoet C. et al. 5-year survival outcomes of the CheckMate 067 phase 3 trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma ESMO, 2019. Annals of Oncology. 2019;30(5 Suppl.):v851–v934. https://doi.org/10.1093/annonc/mdz394.Larkin J.M.G., Chiarion-Sileni V., Gonzalez R., Grob J.J., Rutkowski P., Laoet C. et al. 5-year survival outcomes of the CheckMate 067 phase 3 trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma ESMO, 2019. Annals of Oncology. 2019;30(5 Suppl.):v851–v934. https://doi.org/10.1093/annonc/mdz394.McArthur G.A., Dréno B., Larkin J. 5-year survival update of cobimetinib plus vemurafenib BRAF V600 mutation-positive advanced melanoma: final analysis of the coBRIM study. Presented at: the 16th International Congress of the Society for Melanoma Research; November 20–23, 2019; Salt Lake City, UT.McArthur G.A., Dréno B., Larkin J. 5-year survival update of cobimetinib plus vemurafenib BRAF V600 mutation-positive advanced melanoma: final analysis of the coBRIM study. Presented at: the 16th International Congress of the Society for Melanoma Research; November 20–23, 2019; Salt Lake City, UT.Robert C., Grob J.J., Stroyakovskiy D., Karaszewska B., Hauschild A., Levchenko E. et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019;381(7):626–636. https://doi.org/10.1056/nejmoa1904059.Robert C., Grob J.J., Stroyakovskiy D., Karaszewska B., Hauschild A., Levchenko E. et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019;381(7):626–636. https://doi.org/10.1056/nejmoa1904059.Tarhini A., McDermott D., Ambavane A., Gupte-Singh K., Aponte-Ribero V., Ritchings C. et al. Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma. Immunotherapy. 2019;11(4):283–295. https://doi.org/10.2217/imt-2018-0168.Tarhini A., McDermott D., Ambavane A., Gupte-Singh K., Aponte-Ribero V., Ritchings C. et al. Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma. Immunotherapy. 2019;11(4):283–295. https://doi.org/10.2217/imt-2018-0168.Puzanov I., Amaravadi R.K., McArthur G.A., Flaherty K.T., Chapman P.B., Sosman J.A. et al. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. Eur J Cancer. 2015;51(11):1435–1443. https://doi.org/10.1016/j.ejca.2015.04.010.Puzanov I., Amaravadi R.K., McArthur G.A., Flaherty K.T., Chapman P.B., Sosman J.A. et al. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. Eur J Cancer. 2015;51(11):1435–1443. https://doi.org/10.1016/j.ejca.2015.04.010.Schvartsman G., Taranto P., Glitza I.C., Agarwala S.S., Atkins M.B., Buzaid A.C. Management of metastatic cutaneous melanoma: updates in clinical practice. Ther Adv Med Oncol. 2019;11:1758835919851663. https://doi.org/10.1177/1758835919851663.Schvartsman G., Taranto P., Glitza I.C., Agarwala S.S., Atkins M.B., Buzaid A.C. Management of metastatic cutaneous melanoma: updates in clinical practice. Ther Adv Med Oncol. 2019;11:1758835919851663. https://doi.org/10.1177/1758835919851663.Robert C., Schachter J., Long G.V., Arance A., Grob J.J., Mortier L. et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521–2532. https://doi.org/10.1056/NEJMoa1503093.Robert C., Schachter J., Long G.V., Arance A., Grob J.J., Mortier L. et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521–2532. https://doi.org/10.1056/NEJMoa1503093.Абрамов М.Е., Алиев М.Д., Гафтон Г.И. Демидов Л.В., Жукова Н.В., Новик А.В. и др. Меланома кожи и слизистых оболочек: клинические рекомендации. М.; 2020. 127 с. Режим доступа: https://melanoma.pro/uploads/docs/CR_melanoma_2020_final_compressed.pdf.Abramov M.E., Aliev M.D., Gafton G.I. Demidov L.V., Zhukova N.V., Novik A.V. et al. Melanoma of the skin and mucous membranes: clinical recommendations. Moscow; 2020.127 p. (In Russ.) Available at: https://melanoma.pro/uploads/docs/CR_melanoma_2020_final_compressed.pdf.Франк Г.А., Завалишина Л.Э., Кекеева Т.В., Алексахина C.Н., Гарифуллина Т.Р., Иванцов О.А. и др. Первое Всероссийское молекулярно-эпидемиологическое исследование меланомы: результаты анализа мутаций в гене BRAF. Архив патологии. 2014;76(3):65–73. Режим доступа: https://www.mediasphera.ru/issues/arkhiv-patologii/2014/3/1000419552014031065.Frank G.A., Zavalishina L.E., Kekeyeva T.V., Aleksakhina S.N., Garifullina T.R., Ivantsov O.A. et al. First Russian nationwide molecular epidemiological study for melanoma: results of BRAF mutation analysis. Arkhiv Patologii = Archive of Pathology. 2014;76(3):65–73. (In Russ.) Available at: https://www.mediasphera.ru/issues/arkhiv-patologii/2014/3/1000419552014031065.Ugurel S., Röhmel J., Ascierto P.A., Flaherty K.T., Grob J.J., Hauschild A. et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer. 2017;83:247–257. https://doi.org/10.1016/j.ejca.2017.06.028.Ugurel S., Röhmel J., Ascierto P.A., Flaherty K.T., Grob J.J., Hauschild A. et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer. 2017;83:247–257. https://doi.org/10.1016/j.ejca.2017.06.028.Schachter J., Ribas A., Long G.V., Arance A., Grob J.J., Mortier L. et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853–1862. https://doi.org/10.1016/s0140-6736(17)31601-x.Schachter J., Ribas A., Long G.V., Arance A., Grob J.J., Mortier L. et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853–1862. https://doi.org/10.1016/s0140-6736(17)31601-x.Wolchok J.D., Chiarion-Sileni V., Gonzalez R., Rutkowski P., Grob J.J., Cowey C.L et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma N Engl J Med. 2017;377(14):1345–1356. https://doi.org/10.1056/nejmoa1709684.Wolchok J.D., Chiarion-Sileni V., Gonzalez R., Rutkowski P., Grob J.J., Cowey C.L et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma N Engl J Med. 2017;377(14):1345–1356. https://doi.org/10.1056/nejmoa1709684.Tjulandin S., Fedyanin M., Demidov L., Moiseyenko V., Protsenko S., Odintsova S. et al. Final results of phase II trial (MIRACULUM) of the novel PD-1 inhibitor prolgolimab in patients with advanced melanoma. Annals of Oncology. 2019;30(11 Suppl.):xi33–xi47. https://doi.org/10.1093/annonc/mdz451.Tjulandin S., Fedyanin M., Demidov L., Moiseyenko V., Protsenko S., Odintsova S. et al. Final results of phase II trial (MIRACULUM) of the novel PD-1 inhibitor prolgolimab in patients with advanced melanoma. Annals of Oncology. 2019;30(11 Suppl.):xi33–xi47. https://doi.org/10.1093/annonc/mdz451.Robert C., Schachter J., Long G.V., Arance A., Grob J.-J., Mortier L. et al. Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma. Cancer Res. 2019;79(13 Suppl.). https://doi.org/10.1158/1538-7445.AM2019-CT188.Robert C., Schachter J., Long G.V., Arance A., Grob J.-J., Mortier L. et al. Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma. Cancer Res. 2019;79(13 Suppl.). https://doi.org/10.1158/1538-7445.AM2019-CT188.Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Rutkowski P., Lao C.D. et al. ive-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381(16):1535–1546. https://doi.org/10.1056/nejmoa1910836.Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Rutkowski P., Lao C.D. et al. ive-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381(16):1535–1546. https://doi.org/10.1056/nejmoa1910836.Строяковский Д.Л. Эффективность препарата пролголимаб – что нам известно? В: VI Петербургский международный онкологический форум «Белые ночи». Санкт-Петербург, 25–28 июня 2020.Stroyakovskiy D.L. The effectiveness of the drug prolgolimab – what we need is it known? In: VI St. Petersburg International Oncological Forum "White Nights". St. Petersburg, June 25-28, 2020.La J., Cheng D., Brophy M.T., Do N.V., Lee J.S.N., Tuck D., Fillmore N.R. RealWorld Outcomes for Patients Treated With Immune Checkpoint Inhibitors in the Veterans Affairs System. JCO Clin Cancer Inform. 2020;4:918–928. https://doi.org/10.1200/cci.20.00084.La J., Cheng D., Brophy M.T., Do N.V., Lee J.S.N., Tuck D., Fillmore N.R. RealWorld Outcomes for Patients Treated With Immune Checkpoint Inhibitors in the Veterans Affairs System. JCO Clin Cancer Inform. 2020;4:918–928. https://doi.org/10.1200/cci.20.00084.

The authors declare that there are no conflicts of interest present.